Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum
Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degeneration Benjamin Bakall, MD, PhD, to present 4-year REMAIN extension study data on lasting vision improvement with MCO-010 in...
Covered in this story
What has happened since
- Moody's Corporation is up 0.3% since this was published, 27 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Moody's Corporation
- Jefferies: $484 → $560 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MCO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moody's Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.